
Vibcare Pharma
09/10/26
| Brand | Company | Common pack and MRP (Rs) |
|---|---|---|
| Zerodol P | Ipca Laboratories Ltd | Strip of 10 tablets — ₹75.94 (1mg.com, page stamp 09 Oct 2026) |
| Hifenac P | Intas Pharmaceuticals Ltd | Strip of 15 tablets — ₹117.5 (1mg.com, page stamp 09 Oct 2026). Note: the 1mg listing shows 100 mg + 325 mg, while the Intas leaflet on file (27/09/15) describes Hifenac-P as 100 mg + 500 mg; check the pack in hand. |
| Aceclo Plus | Aristo Pharmaceuticals Pvt Ltd | Strip of 15 tablets — ₹117 (1mg.com, page stamp 09 Oct 2026) |
| Dolokind Plus | Mankind Pharma Ltd | Strip of 15 tablets — ₹85.35 (1mg.com, page stamp 09 Oct 2026) |
| Dolowin Plus | Micro Labs Ltd | Strip of 10 tablets — ₹83.4 (1mg.com, page stamp 09 Oct 2026) |
| Acenac-P | Medley Pharmaceuticals | Strip of 15 tablets — ₹122 (1mg.com, page stamp 09 Oct 2026) |
| Acemiz Plus | Lupin Ltd | Not listed |
| Aldigesic P 100 mg/325 mg | Alkem Laboratories Ltd | Not listed |
| Movexx Plus | Cipla Ltd | Not listed |
| acimol 100 mg/325 mg | Leeford Healthcare Ltd | Not listed |
| Zulu-P, Acyclosure P, Acegesic | Torrent Pharmaceuticals | Not listed |
| Zerodol-SP (100 mg + 325 mg + serratiopeptidase 15 mg) | Ipca Laboratories Ltd | Strip of 10 tablets — ₹150.85 (1mg.com, page stamp 09 Oct 2026) |
| Dolowin-MR (100 mg + chlorzoxazone 250 mg + 325 mg) | Micro Labs Ltd | Strip of 10 tablets — ₹108.7 (1mg.com, page stamp 09 Oct 2026) |
| Dolowin TC 4 (aceclofenac 100 mg + thiocolchicoside 4 mg) | Micro Labs Ltd | Strip of 10 tablets — ₹196.8 (1mg.com, page stamp 09 Oct 2026) |
| Dolowin-SR (aceclofenac 200 mg SR) | Micro Labs Ltd | Strip of 10 SR tablets — ₹96.56 (1mg.com, page stamp 09 Oct 2026) |
All MRPs above are taken from 1mg.com listings carrying the page stamp "Last updated on 09 Oct 2026"; 1mg notes "MRP may vary by batch", and MRPs change over time and between batches.
It is a pain-relief tablet that combines two medicines: the NSAID aceclofenac and the analgesic/antipyretic paracetamol. Indian manufacturers sell it mainly as 100 mg + 325 mg film-coated tablets, and versions with an added muscle relaxant or enzyme are sold under separate brands.
Aceclofenac is a non-steroidal agent with marked anti-inflammatory and analgesic properties. Its mode of action is largely based on the inhibition of prostaglandin synthesis, and it is a potent inhibitor of the enzyme cyclo-oxygenase (Preservex SmPC, section 5.1).
The UK regulator MHRA notes that aceclofenac has little pharmacological activity itself; its main mode of action is through its metabolites, which include diclofenac and 4'-hydroxy diclofenac. After oral dosing it is rapidly and completely absorbed as unchanged drug, with peak plasma levels about 1.25 to 3.00 hours after ingestion and a mean plasma elimination half-life of around 4 hours.
Paracetamol is a mild analgesic and antipyretic recommended for most painful and febrile conditions (UK SmPC, sections 4.1 and 5.1). It has only weak anti-inflammatory properties, and its mechanism of action is not fully understood.
Examples listed on Indian e-pharmacies include 100 mg + 325 mg; 100 mg + 325 mg + serratiopeptidase 15 mg; 100 mg + chlorzoxazone 250 mg + 325 mg; and aceclofenac 100 mg + thiocolchicoside 4 mg. Three-drug tablets with thiocolchicoside are listed as 4 mg / 100 mg / 325 mg per tablet.
Aceclofenac alone is sold as 100 mg tablets and as sustained-release 200 mg tablets. One 100/500 version (100 mg + 500 mg) is described in an Intas leaflet dated 27/09/15. These listings are e-pharmacy pages carrying the stamp 09 Oct 2026, not regulatory documents.
Each source states its own labelled use, and the wording differs between them; the Indian CDSCO-approved indication text for the 100/325 combination could not be verified from a primary CDSCO document. The Indian manufacturer information sheet for the 100 mg + 325 mg combination gives the indication as "For acute painful conditions in adults only", and adds that the fixed-dose combination should be administered under the supervision of physicians.
The UK licensed indication for aceclofenac (Preservex) is relief of pain and inflammation in osteoarthritis, rheumatoid arthritis and ankylosing spondylitis; the MHRA repeats these three conditions. The Intas leaflet for the 100 mg + 500 mg version states it is indicated for the treatment of acute painful inflammatory conditions with or without associated fever. These are source-specific labelled indications and may not match the CDSCO-approved indication for Indian brands.
The paracetamol SmPC recommends paracetamol for most painful and febrile conditions, for example headache including migraine, toothache, neuralgia, colds and influenza, sore throat, backache, rheumatic pain and dysmenorrhoea. Chlorzoxazone is described in its FDA label as an adjunct to rest, physical therapy and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. Thiocolchicoside by mouth or injection is recommended only as adjuvant treatment for acute muscle contractures in spinal pathology, for adults and adolescents from 16 years of age, and not for longer-term treatment of chronic conditions (EMA, 2013).
A 2024 meta-analysis of 22 randomised studies found paracetamol plus aceclofenac reduced pain more than aceclofenac alone in osteoarthritis at the immediate term (mean difference −4.7, 95% CI −8.3 to −1.2; moderate-certainty evidence); the authors conclude that low-to-moderate quality evidence supports some paracetamol plus NSAID combinations for short-term pain relief with no increased risk of harm versus the non-paracetamol comparator.
The dose differs between labels and between brands, so follow the dose your doctor prescribes and the leaflet in your pack; the figures below are the usual adult dose stated in each label quoted and are not personal dose advice.
The usual adult dose stated in the UK label is 200 mg daily, taken as two separate 100 mg doses, one tablet in the morning and one in the evening. It adds that undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms.
For children, there are no clinical data on the use of Preservex in children and therefore it is not recommended for use in children. In the elderly, pharmacokinetics are not altered, so no dose or frequency change is considered necessary, though the lowest effective dose and shortest time are advised with regular monitoring for gastrointestinal bleeding.
In mild renal impairment there is no evidence the dose needs changing, but as with other NSAIDs caution should be exercised. In hepatic impairment some evidence suggests the dose should be reduced, and an initial daily dose of 100 mg is suggested. The label says the tablets are to be taken preferably with or after food, swallowed whole with a sufficient quantity of liquid.
The Torrent information sheet for aceclofenac 100 mg + paracetamol 325 mg states: "The daily recommended dose is one tablet daily for adults" and "It is recommended to take the daily dose in one single intake"; the tablet is swallowed whole with liquid and may be taken with or without food. The Intas leaflet for the 100 mg + 500 mg version states one tablet twice daily, with the maximum recommended dose being two tablets daily; in impaired hepatic function the dose is reduced to one tablet daily.
Both Indian sheets state that there are no clinical data in children: Torrent says the combination is not recommended for use in children, and Intas states there are no clinical data available on the use of aceclofenac in children. In chronic alcoholism, the Torrent sheet says the daily dose of paracetamol should not exceed 2000 mg.
The most commonly observed adverse events with aceclofenac are gastrointestinal in nature. Frequencies below come from the Preservex SmPC: common means 1 in 100 to less than 1 in 10, uncommon 1 in 1,000 to less than 1 in 100, rare 1 in 10,000 to less than 1 in 1,000, and very rare less than 1 in 10,000.
Peptic ulcers, perforation or gastrointestinal bleeding, sometimes fatal and particularly in the elderly, may occur. Serious skin reactions, some of them fatal, have been reported, with the highest risk early in therapy; the label says to stop at the first sign of rash, mucosal lesions or hypersensitivity. NSAIDs may cause a dose-dependent reduction in prostaglandin formation and precipitate renal failure, with effects on renal function usually reversible on withdrawal, and hepatitis may occur without prodromal symptoms.
Oedema, hypertension and cardiac failure have been reported with NSAIDs. The Preservex SmPC states that diclofenac data point to an increased risk of general arterial thrombotic events (for example myocardial infarction or stroke, particularly at high doses or in long treatment), and epidemiological data also found an increased risk of acute coronary syndrome and myocardial infarction with aceclofenac. An EU review estimated about 3 extra heart attacks per year per 1,000 people at moderate risk treated with diclofenac (the metabolite); that figure is for diclofenac, not aceclofenac.
Paracetamol can cause hypersensitivity including skin rash; very rare cases of serious skin reactions are reported. These are not all possible side effects; the product leaflet has the full list. Liver damage is possible in adults who have taken 10 g or more, and 5 g or more may cause liver damage if the patient has risk factors; MedlinePlus warns that taking too much acetaminophen can cause liver damage serious enough to require liver transplantation or cause death.
Chlorzoxazone: serious, including fatal, hepatocellular toxicity has been reported rarely, and the mechanism appears to be idiosyncratic and unpredictable; drowsiness, dizziness, light-headedness, malaise or overstimulation may occur. Thiocolchicoside: the EMA reports that a metabolite may be associated with aneuploidy in dividing cells at exposures not much greater than those achieved with maximum recommended oral doses, which is a risk factor for harm to the developing fetus and reduced male fertility.
Aceclofenac is contraindicated in several groups, and the list below is taken from the Preservex SmPC and the MHRA advice.
Caution and monitoring are advised in bronchial asthma, hepatic porphyria, systemic lupus erythematosus or mixed connective tissue disease, and Crohn's disease or ulcerative colitis. The MHRA advises starting aceclofenac only after careful consideration of risk factors such as hypertension, hyperlipidaemia, diabetes mellitus and smoking.
Aceclofenac is contraindicated in the third trimester, and in the first and second trimester it should not be given unless clearly necessary; from the 20th week it may cause oligohydramnios. It may impair female fertility and is not recommended in women attempting to conceive, and use should be avoided in pregnancy and lactation unless the potential benefits outweigh the possible risks to the foetus.
Paracetamol can be used in pregnancy if clinically needed, at the lowest effective dose for the shortest possible time and at the lowest possible frequency; it is excreted in breast milk but not in a clinically significant amount. MedlinePlus records a September 2025 FDA safety notice that taking acetaminophen while pregnant may be associated with neurological conditions in children, while adding that no evidence to date has shown causation. The Intas leaflet states the drug is not recommended in pregnant and breastfeeding women and is contraindicated in the last three months of pregnancy.
Thiocolchicoside is contraindicated in pregnancy, lactation, women of childbearing potential not using contraception, children, and for chronic conditions; the EMA recommends it only as adjuvant treatment for acute muscle contractures in spinal pathology, for adults and adolescents from 16 years of age. Safe use of chlorzoxazone in pregnancy has not been established.
The Torrent information sheet states that alcohol should not be used during treatment with paracetamol, and in chronic alcoholism the daily paracetamol dose should not exceed 2000 mg. MedlinePlus says not to take acetaminophen if you drink three or more alcoholic drinks every day, and the chlorzoxazone label notes that alcohol or other CNS depressants may have an additive effect.
The Torrent information sheet for the 100 mg + 325 mg combination is headed "To be sold by retail on the prescription of R.M.P. only"; the CDSCO Schedule H status of later brands was not verified. Paracetamol appears in NLEM 2022, while aceclofenac does not.
No NPPA ceiling price for aceclofenac or the 100/325 combination was located. For paracetamol 500 mg tablets, a Department of Pharmaceuticals speaking order records ₹0.94 per tablet on 14 June 2013, revised to ₹1.01 on 2 March 2016, and fixed at ₹0.83 per tablet by NPPA order S.O. 1951(E) dated 2 June 2016; these are historical figures and the current ceiling price was not located from a primary NPPA document. A secondary source reports that an NPPA order of 25 March 2026 fixed revised ceiling prices for scheduled formulations effective 1 April 2026, with a wholesale price index increase of 0.64956% (2025 over 2024), exclusive of GST.
Several companies market the 100 mg + 325 mg combination in India, and the table at the top of this page lists the brands named in the source listings, with their companies, common packs and MRPs. No sales rank is claimed for these brands except where a published source is cited, and readers should compare packs and prices at the time of purchase.
Two published sales references exist. An Ipca corporate presentation of December 2019 states an all-India IQVIA rank of 21st (MAT Dec 2019) and says three Ipca brands were among the top 300 brands, naming HCQS, Zerodol-P and Zerodol-SP. BioSpectrum India, citing PHARMARACK data and published 11 February 2026, reports Zerodol SP monthly sales of ₹67 crore in January 2026, with value growth of 31.2% and unit growth of 22.4%; the article does not state the composition. No published sales-value ranking was found for Hifenac P, Dolokind Plus, Aceclo Plus, Dolowin Plus or other brands in this group.
Vibcare Pharma markets a wide range of aceclofenac-based tablets across its divisions, covering the plain 100 mg + 325 mg tablet, versions with serratiopeptidase 10 mg or 15 mg, chlorzoxazone 250 mg or 500 mg, thiocolchicoside 4 mg, tizanidine 2 mg, rabeprazole 20 mg, drotaverine, trypsin–chymotrypsin and cold-relief combinations, plus aceclofenac 200 mg sustained-release tablets and a 50 mg + 125 mg suspension. Packs come in 10x10 alu-alu and blister and 10x2x10 blister forms.
4 divisions
3 divisions
4 divisions
Prima
Prima
4 divisions
4 divisions
2 divisions
4 divisions
Prima
2 divisions
Genvimax
4 divisions
Evermed
4 divisions
Vibcare Pharma appoints PCD franchise partners district by district, with one partner per district and monopoly rights confirmed in writing.
Add aceclofenac + paracetamol to your range
Vibcare appoints one PCD franchise partner per district, with monopoly rights confirmed in writing. Trade rates for every product are on its product page.
Yes. Aceclofenac is a non-steroidal anti-inflammatory drug with anti-inflammatory and analgesic properties, and paracetamol is a mild analgesic and antipyretic. The Indian manufacturer information sheet for the 100 mg + 325 mg combination gives its use as "For acute painful conditions in adults only", and states it should be administered under the supervision of physicians.
Paracetamol is an antipyretic and is recommended in its UK label for most painful and febrile conditions, and the Intas leaflet for the 100 mg + 500 mg version lists acute painful inflammatory conditions "with or without associated fever". However, the UK aceclofenac label lists only osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, and the Torrent sheet does not mention fever. Ask your doctor what is suitable for your symptoms, and take prescription medicines only as prescribed.
The UK aceclofenac label says the tablets are to be taken preferably with or after food and swallowed whole with a sufficient quantity of liquid, while the Torrent sheet says the combination tablet may be taken with or without food. Because NSAIDs can cause peptic ulcers, perforation or gastrointestinal bleeding at any time, follow the instructions in your pack and the advice of your doctor.
It is contraindicated in renal failure, and NSAIDs may cause a dose-dependent reduction in prostaglandin formation and precipitate renal failure, with effects usually reversible on withdrawal. The UK label advises caution in mild renal impairment and notes higher risk with impaired kidney function, heart or liver problems, diuretics, dehydration and old age, with monitoring of kidney function.
No — the labels advise avoiding concomitant use of two or more NSAIDs including aspirin, as this increases adverse effects including gastrointestinal bleeding, and to avoid combining with COX-2 selective inhibitors. Do not take any other paracetamol-containing product at the same time. Follow your doctor's prescription and the dose stated in the product leaflet; any general paracetamol ceiling (such as the 4000 mg figure in MedlinePlus) is not a dose recommendation for this combination. Always tell your doctor about every medicine you are taking.
The Indian combination sheet states that alcohol should not be used during treatment with paracetamol, and caps paracetamol at 2000 mg a day in chronic alcoholism. MedlinePlus says not to take acetaminophen if you drink three or more alcoholic drinks every day, and the chlorzoxazone label notes that alcohol may have an additive sedative effect.
Aceclofenac is contraindicated in established ischaemic heart disease, peripheral arterial disease, cerebrovascular disease and NYHA II–IV heart failure, and patients in these groups should be switched at their next routine appointment. In people with hypertension, hyperlipidaemia, diabetes mellitus or who smoke, the MHRA advises starting only after careful consideration of these risk factors.
Aceclofenac is contraindicated in the third trimester and should not be given in the first and second trimesters unless clearly necessary; it may impair female fertility and is not recommended in women attempting to conceive. Paracetamol may be used in pregnancy if clinically needed at the lowest effective dose for the shortest possible time, and the Intas leaflet states the combination is not recommended in pregnant and breastfeeding women. Speak to a doctor before taking any medicine in pregnancy.
Add aceclofenac + paracetamol to your range
Vibcare appoints one PCD franchise partner per district, with monopoly rights confirmed in writing. Trade rates for every product are on its product page.
Copy Link